A261780 Stock Overview
Cha Vaccine Research Institute Co., Ltd., a research-oriented biotechnology company, researches and develops a range of vaccine products targeting infectious and chronic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CHA Vaccine Research Institute Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩3,680.00 |
| 52 Week High | ₩6,100.00 |
| 52 Week Low | ₩3,485.00 |
| Beta | 0.70 |
| 11 Month Change | -5.88% |
| 3 Month Change | -18.04% |
| 1 Year Change | -27.84% |
| 33 Year Change | -63.38% |
| 5 Year Change | n/a |
| Change since IPO | -71.69% |
Recent News & Updates
Shareholder Returns
| A261780 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -1.3% | -3.5% | 2.5% |
| 1Y | -27.8% | 24.9% | -1.1% |
Return vs Industry: A261780 underperformed the KR Biotechs industry which returned 24.9% over the past year.
Return vs Market: A261780 underperformed the KR Market which returned -1.1% over the past year.
Price Volatility
| A261780 volatility | |
|---|---|
| A261780 Average Weekly Movement | 3.2% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A261780 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A261780's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Jungsun Yum | www.chavaccine.com |
Cha Vaccine Research Institute Co., Ltd., a research-oriented biotechnology company, researches and develops a range of vaccine products targeting infectious and chronic diseases. Its product pipeline includes HBV vaccine that is in Phase IIb planning for the prevention of hepatitis B; Adjuvanted HBV vaccine that is in Phase I/IIa for the treatment of chronic hepatitis B; and VZV Vaccine, which is in pre-clinical planning stage for the prevention of Herpes Zoster. The company also develops influenza vaccine, recombinant MBL, TB vaccine, and cancer vaccine.
CHA Vaccine Research Institute Fundamentals Summary
| A261780 fundamental statistics | |
|---|---|
| Market cap | ₩98.37b |
| Earnings (TTM) | -₩4.26b |
| Revenue (TTM) | ₩370.66m |
265.4x
P/S Ratio-23.1x
P/E RatioIs A261780 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A261780 income statement (TTM) | |
|---|---|
| Revenue | ₩370.66m |
| Cost of Revenue | ₩23.93m |
| Gross Profit | ₩346.73m |
| Other Expenses | ₩4.61b |
| Earnings | -₩4.26b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -159.36 |
| Gross Margin | 93.54% |
| Net Profit Margin | -1,149.35% |
| Debt/Equity Ratio | 27.8% |
How did A261780 perform over the long term?
See historical performance and comparison